LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

900 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer

NCT03721120

Metastatic Lung Cancer

COMPLETED NA

Molecular Diagnosis of Lung Cancer Via Bronchoscopy: The Significance of Bronchial Liquid Biopsy (ctDNA and ctRNA)

NCT06228508

Non Small Cell Lung Cancer

NOT_YET_RECRUITING

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

NCT01700582

Carcinoma, Non-Small-Cell Lung ALK Gene Mutation KRAS Gene Mutation +1 more

COMPLETED

Liquid Biopsy for Detection of Driver Mutation in NSCLC

NCT02778854

Non Small Cell Lung Cancer

UNKNOWN

Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors

NCT05921474

Non Small Cell Lung Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lung cancers are the first cause of death by cancer in the world. The majority of these patients are diagnosed at a late stage, non-eligible to a curative treatment. Due to tumoral genomic identification, it has been possible to classify NSCLC in molecular subtypes according to molecular abnormalities detection called "drivers" which can be targeted using an appropriate treatment. This change modifies the standard treatments from the very first line of treatment particularly for patients having an EGFR mutation or an ALK or ROS1 rearrangement, with a significant benefit of progression free survival. The French NCI (INCa) recommends to identify genomic alterations of a genes panel including EGFR, KRAS, BRAF, HER2, ALK and ROS1 as well as mutations in MET exon 14. However, all the patients who benefit from a targeted therapy develop resistance after a mean duration of 10-12 months after starting the treatment. In case of progression, the tumour genetic analysis through new biopsies, enables to identify these mechanisms and then to determine if the patient can benefit or not from a third generation molecule active on these mechanisms, and to have a better understanding of the disease evolution.

The detection of these alterations is routinely performed using tissular biopsies but in 10 to 20% of the cases, it is not possible.

The detection of these molecular abnormalities in the plasma, called " liquid biopsy " is a valuable non-invasive complementary approach for these patients. It is presently used in routine for detecting the EGFR mutations at diagnosis as well as for searching EGFR T790M mutation for resistant patients.

The liquid biopsies enable to detect circulating tumoral DNA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Patients with advanced NSCLC and no druggable molecular alteration at time of diagnosis

No interventions assigned to this group

Cohort 2

Patients with advanced NSCLC harboring targetable molecular alterations at time of diagnosis

No interventions assigned to this group

Cohort 3

Patients with advanced NSCLC at time of immunotherapy introduction (1st or 2nd line)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) regardless of the mutation status
* Inclusion at the time of diagnostic
* Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
* Age ≥ 18 years
* Covered by a health insurance
* Signed consent

* Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1 (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification, RET rearrangement.
* Inclusion at the time of diagnosis
* Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
* Age ≥ 18 years
* Covered by a health insurance
* Signed consent

* Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) whatever the mutational or PD-L1 status.
* Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line)
* Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
* Age ≥ 18 years
* Covered by a health insurance
* Signed consent

Exclusion Criteria

\- Patients treated before their liquid biopsy

\- Initiation of immunotherpy before their liquid biopsy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre Saintigny, MD, PhD

Role: STUDY_DIRECTOR

[email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.